Fig. 2

(a) Immunohistochemical (IHC) expression of EZH2 in low, median, and high expressing HGSOC samples at 5x and 20x magnification. (b) Distribution of EZH2 H-score in HGSOC tissues. (c) IHC expression of EZH2 in paired HGSOC and adjacent normal fallopian tube (FT) tissue in representative subject. (d) Boxplots of EZH2 H-score in HGSOC (n = 27) and paired normal epithelium (n = 5) and normal fallopian tube (FT, n = 24) tissues. Groups were compared using the paired t-test. (e) Boxplots of EZH2 H-score in HGSOC and normal appearing FT tissues for subjects with STIC (n = 20) and without STIC (n = 51). Groups were compared using the Wilcoxon two-sample test. (f) Boxplots of HGSOC EZH2 H-score grouped by response to therapy (sensitive/resistant) and presence/absence of TIL. The symbols in the boxplots indicate the mean for (o) resistant and (+) sensitive subgroups. Horizontal line in box interior represents the group median. Groups were compared using the Wilcoxon two-sample test. (g) Adjusted survival curve estimates for EZH2 expression for the lowest quartile (Q1) to the highest quartile (Q4) using cox proportional hazards regression. Adjustments include age, stage, and response to therapy. Statistical significance of boxplot comparisons is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.0001